Earl Howe Appointed As ICR President
News Oct 20, 2008
In his new role Earl Howe will not only be a figurehead for the ICR but he will also act as an ambassador for the clinical research industry helping to provide introductions to key advocates. His position within Parliament will also offer ICR opportunities to hold top level briefings and events with parliamentary contacts helping to influence industry policies.
Earl Howe has been the opposition spokesperson for health and social services in the House of Lords for more than 10 years, he has extensive knowledge of the medical and clinical research industry and is a member of the pharmaceuticals and mental health all-party groups.
On his new role, Earl Howe, said: “I am delighted to be appointed president of the ICR. I have long had a professional interest in clinical research and I am personally relishing the opportunity of helping to further raise the profile of this important area of medicine.
“I have already met with the ICR’s chair Susan Ollier, chief executive Dr John Hooper and the rest of the board and I am inspired by their enthusiasm and drive for improvements in the industry.”
Susan Ollier, chair of the ICR, is looking forward to working with Earl Howe. She commented: “Earl Howe is the first president of the ICR and his appointment in the organisation’s 30th year of operation reflects the mature position and stature that the Institute has reached in its development.
“To support the appointment of Earl Howe, we will be appointing a vice-president, based in mainland Europe, to help support our expanding membership base in Europe and continue to widen the learning and development opportunities for our members.”
The ICR is the largest professional clinical research body in Europe and India. Its vision is to be internationally recognised as the premier organisation for clinical research and respected as a key influencer, promoting knowledge and understanding throughout the industry.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
CBD Significantly Reduces Seizures in Patients with Severe Form of EpilepsyNews
Large-scale clinical trial finds cannabidiol can dramatically reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome.
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018